Article Text

Download PDFPDF
Oestrogen plus progestogen did not prevent cardiovascular disease in postmenopausal women

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

OpenUrlCrossRefPubMedWeb of Science

Q Does oestrogen plus progestogen reduce the risk of coronary heart disease (CHD) in postmenopausal women?


Embedded ImageDesign:

randomised placebo controlled trial.

Embedded ImageAllocation:


Embedded ImageBlinding:

blinded {patients, clinicians, data collectors, outcome assessors, and monitoring committee}*.

Embedded ImageFollow up period:

mean 5.6 years.

Embedded ImageSetting:

{40 clinical centres in the US}*.

Embedded ImagePatients:

16 608 postmenopausal women who were 50–79 years of age (mean age 63 y), had an intact uterus, and resided in the same geographic area for ⩾3 years.

Embedded ImageInterventions:

1 daily tablet of oral conjugated equine oestrogen, 0.625 mg, plus medroxyprogesterone acetate (Prempro, Wyeth Ayerst, Philadelphia, PA, USA), 2.5 mg, (n = 8506) or placebo (n = 8102).

Embedded ImageOutcomes:

CHD defined as acute myocardial …

View Full Text


  • * OpenUrl

  • For correspondence: Dr J E Manson, Division of Preventive Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA.

  • Source of funding: National Heart, Lung, and Blood Institute.

  • A modified version of this abstract appears in ACP Journal Club.